3-Fluoro-4-{[2-(3-fluoro-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carbonyl]-amino}-benzimidic acid methyl ester | 684270-97-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-Fluoro-4-{[2-(3-fluoro-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carbonyl]-amino}-benzimidic acid methyl ester
• CAS: 684270-97-1
• 化学式: C₂₃H₁₈F₂N₄O₂
• 分子量: 420.418
• InChiKey: NIFNMIHRODCXRM-UHFFFAOYSA-N

物化性质

• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.84
• 重原子数：
  31.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  80.0
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  3-Fluoro-4-{[2-(3-fluoro-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carbonyl]-amino}-benzimidic acid methyl ester 在 氨 作用下， 以 甲醇 为溶剂， 生成 2-(3-Fluoro-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid (4-carbamimidoyl-2-fluoro-phenyl)-amide
  参考文献：
  名称：

  1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors

  摘要：

  Using N,N-dialkylated benzamidines as the novel P4 motifs, we have designed and synthesized a class of 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent and selective fXa inhibitors with significantly improved hydrophilicity and in vitro anticoagulant activity. These benzamidine-P4 fXa inhibitors have displayed excellent oral bioavailability and long half-life. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.054
• 作为产物：
  描述：

  3-氟-4-氨基苯腈 在 盐酸 、 三甲基铝 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 生成 3-Fluoro-4-{[2-(3-fluoro-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carbonyl]-amino}-benzimidic acid methyl ester
  参考文献：
  名称：

  1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors

  摘要：

  Using N,N-dialkylated benzamidines as the novel P4 motifs, we have designed and synthesized a class of 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent and selective fXa inhibitors with significantly improved hydrophilicity and in vitro anticoagulant activity. These benzamidine-P4 fXa inhibitors have displayed excellent oral bioavailability and long half-life. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.054